Evaluation of circadian phenotypes utilizing fibroblasts from patients with circadian rhythm sleep disorders

A Hida1, Y Ohsawa1, S Kitamura1, K Nakazaki1, N Ayabe1, Y Motomura1,2, K Matsui3, M Kobayashi3,4, A Usui3, Y Inoue3,4, H Kusanagi5, Y Kamei6 and K Mishima1

We evaluated the circadian phenotypes of patients with delayed sleep–wake phase disorder (DSWPD) and non-24-hour sleep–wake rhythm disorder (N24SWD), two different circadian rhythm sleep disorders (CRSDs) by measuring clock gene expression rhythms in fibroblast cells derived from individual patients. Bmal1-luciferase (Bmal1-luc) expression rhythms were measured in the primary fibroblast cells derived from skin biopsy samples of patients with DSWPD and N24SWD, as well as control subjects. The period length of the Bmal1-luc rhythm (in vitro period) was distributed normally and was 22.80 ± 0.47 (mean ± s.d.) h in control-derived fibroblasts. The in vitro periods in DSWPD-derived fibroblasts and N24SWD-derived fibroblasts were 22.67 ± 0.67 h and 23.18 ± 0.70 h, respectively. The N24SWD group showed a significantly longer in vitro period than did the control or DSWPD group. Furthermore, in vitro period was associated with response to chronotherapy in the N24SWD group. Longer in vitro periods were observed in the non-responders (mean ± s.d.: 23.59 ± 0.89 h) compared with the responders (mean ± s.d.: 22.97 ± 0.47 h) in the N24SWD group. Our results indicate that prolonged circadian periods contribute to the onset and poor treatment outcome of N24SWD. In vitro rhythm assays could be useful for predicting circadian phenotypes and clinical prognosis in patients with CRSDs.

Translational Psychiatry (2017) 7, e1106; doi:10.1038/tp.2017.75; published online 25 April 2017

INTRODUCTION

Circadian rhythm sleep disorders (CRSDs) are defined by persistent or recurrent disturbed sleep–wake patterns and consist of several subtypes including advanced sleep–wake phase disorder (ASWPD), delayed sleep–wake phase disorder (DSWPD), and non-24-hour sleep–wake rhythm disorder (N24SWD). ASWPD is characterized by extremely early involuntary sleep timing, whereas DSWPD is characterized by significantly delayed sleep timing, and N24SWD has sleep timing that occurs with a 30 min to 1 h delay each day. CRSDs have a high rate of comorbidity with various psychiatric disorders, especially mood disorders. A previous study showed that approximately half of their patients with N24SWD developed psychiatric problems before or after the onset of N24SWD. CRSDs are thought to result from impairment of the circadian clock system and/or a misalignment between the endogenous circadian rhythm and exogenous entrainment factors that affect sleep timing. Patients with CRSDs are mostly treated with chronotherapy, in which intense light exposure or melatonin administration is performed during the phase-advance or phase-delay portion, respectively, of the sleep–wake cycle. In mammals, the central oscillator in the suprachiasmatic nucleus of the hypothalamus incorporates environmental cues, such as light exposure, and coordinates the phase of oscillators in peripheral tissues. The molecular mechanisms underlying the circadian clock system involve the transcription–translation negative feedback loops of multiple clock genes including BMAL1, CLOCK, CRY, PER, ROR and REV-ERB.

Evaluating the circadian phenotype is crucial for establishing a precise clinical diagnosis and for understanding the pathophysiology of diseases that are associated with disturbed biological rhythms such as CRSDs. The intrinsic circadian period, \( \tau \) (the free-running period of circadian rhythms in the absence of external cues), is considered to be a critical factor in the pathophysiology of CRSDs. In fact, we found that the \( \tau \) determined under a forced desynchrony protocol was longer in patients with N24SWD than it was in healthy subjects with an intermediate chronotype. However, the forced desynchrony protocol is costly and laborious, and thus different approaches that can provide more convenient and feasible methods of evaluating circadian phenotypes in a clinical setting are needed.

Surrogate measurement techniques, such as using cultured cells derived from biopsy samples of an individual, have been developed and tested for assessing circadian phenotypes. We recently measured clock gene expression rhythms (in vitro rhythms) in primary fibroblasts obtained from skin biopsy samples of healthy subjects and compared the period length of in vitro rhythms (the in vitro period) with the subjects’ circadian/sleep parameters, as evaluated by questionnaires, sleep logs and actigraphy. The results showed that the in vitro period was significantly correlated with subjects’ chronotypes and habitual sleep time. Our data suggest that evaluating the in vitro period may be useful for predicting circadian phenotypes. However, the approach of using isolated cultured cells has not yet been applied to assess patients with CRSDs. Therefore, in the present study, we examined the circadian phenotypes of patients with DSWPD and...
N24SWD by evaluating Bmal1-luciferase (Bmal1-luc) rhythms in skin fibroblast cells from individual patients.

MATERIALS AND METHODS

Subjects

The study population consisted of 41 individuals with DSWPD (29 men; mean ± s.d. age: 32.14 ± 9.86 years and 12 women; mean ± s.d. age: 33.08 ± 13.28 years), 26 individuals with N24SWD (17 men; mean ± s.d. age: 28.82 ± 8.60 years and 9 women; mean ± s.d. age: 30.33 ± 14.44 years) and 14 controls (50 men; mean ± s.d. age: 27.06 ± 7.42 years; Supplementary Tables S1–S3). All subjects were recruited at medical and research institutes on mainland Japan and were sighted individuals. The patients with DSWPD and N24SWD were clinically diagnosed by trained psychiatrists according to the International Classification of Sleep Disorders, 2nd Edition. Controls were healthy individuals with intermediate chronotypes (mean ± s.d. morningness–eveningness questionaire (MEQ) score: 50.89 ± 4.04). The Japanese version of the Home–Östberg MEQ was used to assess control subjects’ chronotypes. Because an individual’s morningness–eveningness preference changes with age, the MEQ scores were adjusted by age (age-adjusted MEQ score: MEQ score +0.3512× (39.212–age)). The protocol was approved by the Institutional Ethics Committee of the National Center of Neurology and Psychiatry, and written informed consent was obtained from all the subjects. The present study was conducted according to the principles of the Declaration of Helsinki.

Skin biopsy, cell culture and in vitro rhythm assay

The experimental procedures were performed according to our previous study. Briefly, for each measurement, 1×10⁶ primary fibroblast cells derived from a skin biopsy sample were transfected with 5 μg of the Bmal1-luc reporter construct Bp/S27-LUC using Neon (Thermo Fisher Scientific, Waltham, MA, USA) and were plated in a 35 mm culture dish. After 14 days, the cells were treated with 0.1 μg dexamethasone (Sigma-Aldrich, St. Louis, MO, USA) for 2 h to synchronize the rhythms in the fibroblasts. Luminescence from the cells was measured in recording medium using a LumiCycle (Actimetrics, Wilmette, IL, USA). The period length of the Bmal1-luc rhythm (in vitro period) was determined by regression analysis as previously reported. The luminescence data were detrended by subtracting the 24 h moving average from the raw data and then was smoothed by 2 h adjacent average. The acrophase of the in vitro rhythm was calculated using ClockLab (Actimetrics). A linear regression line was determined using acrophases for the second, third and fourth cycles of the in vitro rhythm. The slope of the regression line indicates the in vitro period (Figure 1). The in vitro period for each subject was determined as the mean of three to six independent measurements. The in vitro periods in the control, DSWPD and N24SWD groups are presented as mean ± s.d.

Chronotherapy and treatment response

Chronotherapy consisted of high-intensity light therapy and the administration of melatonin or a melatonin receptor agonist (ramelteon) as previously described. Less than 6 h after waking up, the patients were exposed to high-intensity light (5000–8000 lx) for 2–3 h. The patients took 1, 0.5 and 0.5 mg of melatonin 7, 5.5 and 4 h, and took 4 mg of ramelteon 7 h, before going to bed on the previous day. The patients kept their sleep diaries during the therapy. Mid-sleep time was designated as the midpoint between sleep-onset time and wake time. Patients with DSWPD were considered to have responded to the therapy if their mid-sleep times during the therapy were entrained to their desired times for four consecutive weeks. The circadian period (τ) of the sleep–wake cycle was calculated by performing linear regression analysis using mid-sleep times as previously described. Patients with N24SWD were considered to have responded if the τ of the 4-week sleep–wake cycle during the therapy was 24.1 h or less, as described for the tasimelteon clinical trials. Mid-sleep time and τ are presented as mean ± s.d.

Statistical analysis

Kolmogorov–Smirnov tests were performed and frequencies for the parameters tested in this study were normally distributed. Levene’s tests were performed and Welch’s correction for unequal variances was applied to t-test. One-way analyses of variance and Bonferroni post hoc testing were performed to compare the in vitro periods among the DSWPD, N24SWD and control groups (Figure 2). One-tail unpaired t-tests were used to compare the in vitro period of the responders with that of the non-responders in each of the DSWPD and N24SWD groups (Figure 3). P < 0.05 was considered to be statistically significant. Data analysis was performed using ORIGIN9 (OriginLab, Northampton, MA, USA).

RESULTS

The Bmal1-luc rhythms were measured in the fibroblast cells derived from patients with DSWPD, patients with N24SWD and control subjects. The period length of the Bmal1-luc rhythm (in vitro period) varied among individuals. The in vitro period ranged from 21.35 to 24.04 h (mean ± s.d.: 22.80 ± 0.47 h) in control broblast samples, from 22.05 to 24.83 h (mean ± s.d.: 23.18 ± 0.67 h) in N24SWD broblast samples and from 21.96 to 24.08 h (mean ± s.d.: 22.80 ± 0.47 h) in control fibroblast samples (Figure 2). The in vitro period differed significantly among the three groups (F(2,114) = 4.37, P = 0.003). A prolonged in vitro period was observed in the N24SWD group compared with the control (Bonferroni-corrected P = 0.029) or DSWPD group (Bonferroni-corrected P = 0.002). In contrast, no difference in the in vitro period was observed between the DSWPD and control groups. Patients with CRSs underwent chronotherapy. In some patients, the CRSD was intractable and they were considered to be non-responders. The relationship between treatment response and in vitro period were assessed in the DSWPD and N24SWD groups (Table 1 and Figure 3). The in vitro period did not differ between the responders and the non-responders in the DSWPD group (22.73 ± 0.77 h vs 22.58 ± 0.51 h; t = 0.69, df = 39, one-tailed P = 0.246) but did differ in the N24SWD group (22.97 ± 0.47 h vs 23.59 ± 0.89 h; t = 1.95, df = 10.42, one-tailed P = 0.039 (Welch correction)). The in vitro period of the non-responders was longer than that of the responders in the N24SWD group. Detailed information of the control subjects and patients is shown in Supplementary Tables S1–S3.

Figure 1. Representative detrended data of Bmal1-luc rhythm (in vitro rhythm) in cultured fibroblasts from a control subject. (a) A linear regression line (dotted line) was calculated using acrophase times for the second cycle (A2), third cycle (A3) and fourth cycle (A4) of the in vitro rhythm. (b) The period length of the Bmal1-luc rhythm (in vitro period) was determined from the slope of the regression line.
that the in vitro period was significantly longer in the N24SWD group than it was in the control group. These findings are consistent with our previous study, which demonstrated that the period length is not a primary factor in patients with the DSWPD phenotype. Theoretically, a longer period would result in continuous phase delays in the sleep–wake cycle, which is the typical phenotype of N24SWD. However, a prolonged in vitro period was not necessarily observed in all of the N24SWD fibroblast samples. This indicates that other factors have a role in the N24SWD phenotype. For instance, impaired photic entrainment of the circadian clock is considered to be one factor that leads to the onset of N24SWD, as nearly 50% of completely blind individuals show free-running sleep–wake patterns. In contrast, the in vitro period of the DSWPD and control groups did not differ. This finding suggests that circadian period length is not a primary factor in patients with the DSWPD phenotype. It has been proposed that alterations in circadian entrainment mechanisms could lead to the onset of DSWPD. Possible altered mechanisms include reduced phase advance and/or enhanced phase delay of the sleep–wake cycle and decreased phase-advance portion and/or increased phase-delay portion of the sleep–wake cycle.

In accordance with the results of previous reports, our patients with CRSDs varied in their responses to chronotherapy. Notably, the chronotherapy non-responders had a longer in vitro period compared with the responders. This finding suggests that longer in vitro period might predict poorer treatment response in patients with N24SWD. McCarthy et al. previously measured in vitro rhythms in the fibroblast cells from bipolar disorder patients and examined the effect of the mood stabilizer lithium on in vitro rhythms. They found prolonged period length of in vitro rhythm and reduced responsiveness to lithium in bipolar disorder fibroblast samples. The relationship between in vitro period length and clinical response to lithium treatment was not assessed as the clinical data were not available in their study. Pharmacological assays using isolated fibroblasts might be useful for evaluating responsiveness to therapeutic agents and impairment of circadian entrainment mechanism in patients with CRSDs.
been previously reported, though, that the in vitro period did not differ between young healthy subjects (11 men and 7 women; mean ± s.d. age: 25.44 ± 3.58 years) and old healthy subjects (11 men and 7 women; mean ± s.d. age: 67.89 ± 7.32 years). Thus, we believe that neither sex nor age would have influenced in vitro period. Responders and non-responders to chronotherapy were classified on the basis of r of the sleep–wake cycle. Previous studies have, however, shown that sleep–wake rhythms do not always synchronize with the melatonin-secretion rhythm known as a circadian phase marker. Evaluating physiological rhythms as well as sleep–wake rhythms would be required to demonstrate that in vitro period could serve as a reliable molecular marker for the treatment outcome of CRSs.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGMENTS
We thank Dr Masaaki Ikeda for providing the Bmal1-luc reporter construct Bp/S27-LUC, Dr Shin Yamazaki and Dr Yu-ichi Goto for their technical advice; and Mie Kato, Junko Minami and Hiroko Ono for their technical assistance; and Hiroko Takeda, Keiko Hiyama, Kentaro Nozaki and Chihaya Osawa for their support. Part of this study was supported by Grants-in-Aid for Scientific Research (24621015, 15K09817, #25293255 and #16H05381) from the Japan Society for the Promotion of Science, Intramural Research Grant (#23-3 and #26-2) for Neurological and Psychiatric Disorders from the National Center of Neurology and Psychiatry, a Grant-in-Aid (H22-23 Hida A, Kitamura S, Ohwada Y, Enomoto M, Katayose Y, Morotomo Y and et al. in vitro circadian period is associated with circadian/sleep preference. Sci Rep 2013; 3: 2074.

REFERENCES
1 Barion A, Zee PC. A clinical approach to circadian rhythm sleep disorders. Sleep Med 2007; 8: 566–577.
2 Okawa M, Uchiyama M. Circadian rhythm sleep disorders: characteristics and entrainment pathology in delayed sleep phase and non-24-h sleep–wake syndrome. Sleep Med Rev 2007; 11: 485–496.
3 Hida A, Kitamura S, Mishima K. Pathophysiology and pathogenesis of circadian rhythm sleep disorders. J Physiol Anthropol 2012; 31: 7.
4 Ebisawa T. Analysis of the molecular pathophysiology of sleep disorders relevant to a disturbed biological clock. Mol Genet Genomics 2013; 288: 185–193.
5 Thorspy MJ, Koman E, Spielman AJ, Glovinsky PB. Delayed sleep phase syndrome in adolescents. J Adolesc Health Care 1988; 9: 22–27.
6 Regensteiner JR, Monk TH. Delayed sleep phase syndrome: a review of its clinical aspects. Am J Psychiatry 1995; 152: 602–608.
7 Hayakawa T, Uchiyama M, Kamei Y, Shibui K, Tagaya H, Asada T et al. Clinical analyses of sighted patients with non-24-hour sleep–wake syndrome: a study of 57 consecutively diagnosed cases. Sleep 2005; 28: 945–952.
8 Brown MA, Quan SF, Eichling PS. Circadian rhythm sleep disorder, free-running type in a sighted male with severe depression, anxiety, and agoraphobia. J Clin Sleep Med 2011; 7: 93–94.
9 Lowrey PL, Takahashi JS. Mammalian circadian biology: elucidating genome-wide levels of temporal organization. Annu Rev Genomics Hum Genet 2004; 5: 407–441.
10 Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature 2002; 418: 935–941.
11 Kitamura S, Hida A, Enomoto M, Watanabe M, Katayose Y, Nozaki K et al. Intrinsic circadian period of sighted patients with circadian rhythm sleep disorder, free-running type. Biol Psychiatry 2013; 73: 63–69.
12 Czeisler CA, Duffy JF, Shanahan TL, Brown EN, Mitchell JF, Rimmer DW et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science 1999; 284: 2177–2181.
13 Klemer EB, Dijk DJ, Kronauer RE, Czeisler CA. Simulations of light effects on the human circadian pacemaker: implications for assessment of intrinsic period. Am J Physiol 1996; 270(1 Pt 2): R271–R282.
14 Hida A, Kitamura S, Ohwada Y, Enomoto M, Katayose Y, Motomura Y and et al. in vitro circadian period is associated with circadian/sleep preference. Sci Rep 2013; 3: 2074.
15 Hasan S, Santhi N, Lazar AS, Slak A, Lo J, von Schantz M et al. Assessment of circadian rhythms in humans: comparison of real-time fibroblast reporter imaging with plasma melatonin. FASEB J 2012; 26: 2414–2423.
16 Pagani L, Schmitt K, Meier F, Izakovic J, Roemer K, Viola A et al. Serum factors in older individuals change cellular clock properties. Proc Natl Acad Sci USA 2011; 108: 7218–7223.
17 Pagani L, Senenova EA, Moriggi E, Revell VL, Hack LM, Lockley SW et al. The physiological period length of the human circadian clock in vivo is directly proportional to period in human fibroblasts. PLoS ONE 2010; 5: e13376.
18 Brown SA, Fleury-Olela F, Nagoshi E, Hauser C, Juge C, Meier CA et al. The period length of fibroblast circadian gene expression varies widely among human individuals. PLoS Biol 2005; 3: e138.
19 Brown SA, Kunz D, Dumas A, Westermarck PO, Vanselow K, Tilmann-Waehnchaffe A et al. Molecular insights into human daily behavior. Proc Natl Acad Sci USA 2008; 105: 1602–1607.
20 American Academy of Sleep Medicine. The International Classification of Sleep Disorders, 2nd Edition. (ICSD-2); Westchester, IL, USA, 2005.
21 Ishihara K, Saito T, Inoue Y, Miyata Y. Validity of the Japanese version of the Circadian Rhythm Sleep Disorders from the National Center of Neurology and Psychiatry, a Grant-in-Aid (H22-SeisakuSouseiyaku-Ippan-013) from the Ministry of Health, Labour and Welfare and a grant from the Takeda Research Foundation.

Table 1. In vitro period and sleep pattern of responders and non-responders in DSWPD and N24SWD

|                  | DSWPD          | N24SWD         |
|------------------|----------------|----------------|
|                  | In vitro period (h) | Mid-sleep time (h) | N | In vitro period (h) | r (h) |
| Responders       | 22.73 ± 0.77     | 3.90 ± 1.06     | 17 | 22.97 ± 0.47     | 23.94 ± 0.07 |
| Non-responders   | 22.58 ± 0.51     | 5.97 ± 1.12     | 9  | 23.59 ± 0.89     | 24.48 ± 0.37 |

Abbreviations: DSWPD, delayed sleep–wake phase disorder; N, number of subjects; N24SWD, non-24-hour sleep–wake rhythm disorder; r, circadian period of the sleep–wake cycle during the chronotherapy. *p < 0.05 between responders and non-responders. Mid-sleep time represents the midpoint between sleep-onset time and wake time during the chronotherapy. Data are presented as mean ± s.d.
30 Kamei Y, Hayakawa T, Urita J, Uchiyama M, Shibui K, Kim K et al. Melatonin treatment for circadian rhythm sleep disorders. *Psychiatry Clin Neurosci* 2000; **54**: 381–382.

31 McCarthy MJ, Wei H, Mamoy Z, Darvish RM, McPhie DL, Cohen BM et al. Genetic and clinical factors predict lithium’s effects on PER2 gene expression rhythms in cells from bipolar disorder patients. *Transl Psychiatry* 2013; **3**: e318.

32 Jones CR, Campbell SS, Zone SE, Cooper F, DeSano A, Murphy PJ et al. Familial advanced sleep-phase syndrome: a short-period circadian rhythm variant in humans. *Nat Med* 1999; **5**: 1062–1065.

33 Toh KL, Jones CR, He Y, Eide EJ, Hinz WA, Virshup DM et al. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. *Science* 2001; **291**: 1040–1043.

34 Vanselow K, Vanselow JT, Westermark PO, Reischl S, Maier B, Korte T et al. Differential effects of PER2 phosphorylation: molecular basis for the human familial advanced sleep phase syndrome (FASPS). *Genes Dev* 2006; **20**: 2660–2672.

Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)